The story of how Franklin Pharmacy became a new brand in the world of pharmacy tech.
A year after its opening, the first drug to be a new drug is already being marketed in Franklin, Ohio.
The new product is called Empower, a drug that delivers high levels of oxygen in a pill.
The product, developed by Franklin pharmacist Scott Haggerty, has been gaining popularity in the past few months, according to a recent New York Times article.
The Franklin pharmacy has sold over 5,000 pills in just three weeks, and more than 1,000 of those were delivered to patients.
Franklin is one of many in the nation that have started to embrace the drug.
In recent months, other Ohio counties including Cleveland and Cincinnati have begun testing Empower.
Haggerly said he believes it will be in the U.S. by the end of the year.
“I think it’s a great start,” he said.
“We have a lot of great products in the marketplace and this is the first one to be tested in Ohio.
We’re looking forward to having more customers.”
The Ohio Pharmacy Association has been lobbying for Empower for years.
Its president, Gary Schmitt, said he sees the drug as a first step to making prescription medication more accessible.
“This is a first of its kind for us, a first for us as an industry, and this will allow us to really take our game to the next level,” Schmitt said.
The Ohio pharmacist also said the drug is one step closer to becoming the first U.K.-made drug to reach the U of L in its new pharmacy.
The U of Louisville’s Pharmacy and Pharmacy Tech is testing Empowered.
A study conducted by the university’s Pharmacist and Pharmacist Education Program showed the drug has been approved by the UofL and U.C.L.A. to treat chronic obstructive pulmonary disease, a condition that can lead to lung cancer.
Haggerty said he hopes to begin shipping Empower next month.
He said he’s hoping the drug will also help other patients with chronic obstructions.
“It will be the first medicine that really addresses the issue of chronic obstructives,” he explained.
“I’m very hopeful for people who suffer from chronic obstructivity.”Read more